Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Severe Parkinsonism and Creatine Kinase Increase After Low-Dose Aripiprazole Treatment in a Patient of African Descent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Off-Label Prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inhibitory Control in Children with Tourette Syndrome Is Impaired in Everyday Life but Intact during a Stop Signal Task

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reduced prefrontal cortex response to own vs. unknown emotional infant faces in mothers with bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE/BACKGROUND: The aim of this study was to examine the association between genetically predicted CYP2D6 phenotypes and extrapyramidal symptoms (EPSs).

METHODS/PROCEDURES: Data from the Tolerability and Efficacy of Antipsychotics trial of adolescents with first-episode psychosis randomized to aripiprazole versus quetiapine extended release were studied. Extrapyramidal symptom assessments included the Simpson-Angus Scale and the Barnes Akathisia Rating Scale. Patients were CYP2D6 genotyped. Plasma concentrations of antipsychotics and antidepressants were analyzed.

FINDINGS/RESULTS: One hundred thirteen youths (age, 12-17 years; males, 30%; antipsychotic naive, 51%) were enrolled. Poor metabolizers had a significantly higher dose-adjusted aripiprazole plasma concentration (±SD) compared with normal metabolizers at week 4 (24.30 ± 6.40 ng/mL per milligram vs 14.85 ± 6.15 ng/mL per milligram; P = 0.019), but not at week 12 (22.15 ± 11.04 ng/mL per milligram vs 14.32 ± 4.52 ng/mL per milligram; P = 0.067). This association was not found in the quetiapine extended release group. No association between CYP2D6 genotype groups and global Barnes Akathisia Rating Scale score or Simpson-Angus Scale score was found in any of the treatment arms.

IMPLICATIONS/CONCLUSIONS: Our results do not support routine use of CYP2D6 testing as a predictor of drug-induced parkinsonism or akathisia risk in clinical settings. Further studies with larger samples of CYP2D6 poor metabolizers are needed.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Psychopharmacology
Vol/bind41
Udgave nummer6
Sider (fra-til)667-672
Antal sider6
ISSN0271-0749
DOI
StatusUdgivet - nov. 2021

Bibliografisk note

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ID: 68917714